Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved

AI Briefing

• – Curatis Holding AG reports 57% revenue growth to CHF 10.8m in 2025, with organic sales increasing 13%. The company's net loss narrowed to CHF 1.4m, improving from CHF 4.3m in 2024. A FDA meeting in September validated Curatis' development plan for corticorelin, paving the way for regulatory approval.